Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2017 | What does the future treatment landscape of myeloma look like?

Michele Cavo • 21 Apr 2017
COMy 2017
Multiple Myeloma Selinexor Venetoclax

Michele Cavo, MD, from the Bologna University School of Medicine, Bologna, Italy, discusses ongoing research for multiple myeloma (MM) and penta-refractory disease. Prof. Cavo mentions new drugs and new classes of drugs, such as selinexor and venetoclax, which are currently being tested in clinical trials. He believes the future to be promising as we have new drugs and new classes of drugs to explore, and he expects new information about the status of these drugs to rapidly become available in upcoming meetings.
Recoded at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

More from Michele Cavo

1:37
Treatment options for patients with triple-class refractory myeloma: the value of immunotherapy
Michele Cavo • 28 Sep 2023
1:36
The importance of MRD as a prognostic tool in multiple myeloma
Michele Cavo • 28 Sep 2023
1:24
CD38-targeting triplets for myeloma
Michele Cavo • 17 May 2022
1:43
How has the role of transplant changed with the introduction of CAR-T therapy?
Michele Cavo • 17 May 2022

Related Videos

4:59
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
Ola Landgren • 13 Apr 2024
1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
The content of VJHemOnc is intended for healthcare professionals